Novavax Inc. said on Oct. 27 the company had completed the real-time submission of an application for the authorization of the Covid-19 vaccine candidate NVX-CoV2373 in the United Kingdom.

Shares of Novavax Inc. fell 16 percent after a report from Politico said the company faces significant hurdles in proving it can manufacture the experimental Covid-19 vaccine NVX-CoV2373 that meets regulators’ quality standards, resulting in production delays.

Vaccine developer Novavax Inc. said on Sept. 10 at least 2 billion doses of the company’s Covid-19 vaccine would be available in 2022.

Vaccine developer Novavax Inc. said on Sept. 8 the company initiated an early-stage study to test a combination of the flu shot NanoFlu and the Covid-19 vaccine NVX-CoV2373.

Participants in Novavax Inc.’s late-stage Covid-19 vaccine trial can be considered fully vaccinated two weeks after completing their two-dose vaccine regimen, the U.S. Centers for Disease Control and Prevention said on Aug. 30.

Novavax Inc. on Aug. 5 again delayed the company’s timeline for seeking U.S. authorization for its two-dose Covid-19 vaccine, but expects to become a major distributor to lower and middle-income countries this year.

Novavax Inc. said vaccine efficacy appeared to be preserved in those receiving an approved influenza vaccine along with the company’s Covid-19 vaccine candidate compared to those receiving its Covid-19 vaccine alone.

Novavax Inc. on June 14 reported late-stage data from the company’s U.S.-based clinical trial showing its vaccine is more than 90 percent effective against Covid-19 across a variety of variants of the virus.

Novavax Inc.’s experimental Covid-19 vaccine showed immune response and protection against the highly contagious coronavirus variant originally identified in South Africa in a clinical trial.

Novavax Inc. said on May 10 the company’s combined flu and Covid-19 vaccine produced functional antibodies against influenza and the coronavirus in a preclinical study.